Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081167 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
A Phase 3 study of Major Depressive Disorder, sponsored by Relmada Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
- 10
- Study locations
NCT05081167: Completed Phase 3 study of Major Depressive Disorder, sponsored by Relmada Therapeutics.
NCT05081167 is a Phase 3 study of Major Depressive Disorder that has completed, run by Relmada Therapeutics. The registered enrollment target is 232 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (38% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05081167, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Relmada Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
Primary Outcome
Therapeutic efficacy of REL-1017 as monotherapy versus placebo in the Montgomery-Asberg Depression Rating Scale (MADRS10). A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. A negative change from baseline indicates improvement.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REL-1017
Study Locations (10)
Florida
- Relmada Site - Maitland
- Relmada Site - Miami
- Relmada Site - Miami
- Relmada Site - Miami Springs
- Relmada Site - Orlando
- Relmada Site - Palm Bay
Massachusetts
- Relmada Site - Boston
- Relmada Site - Watertown
Illinois
- Relmada Site - Chicago
Texas
- Relmada Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 3 |
What the finished NCT05081167 record still lists
NCT05081167 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05081167 lists 10 locations in 4 states (Florida, Massachusetts, Illinois).
Frequently Asked Questions
What is clinical trial NCT05081167 about?
NCT05081167 is a clinical study titled "A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)". This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
What is the current status of trial NCT05081167?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2021-06-02. Estimated completion is 2022-09-14.
What conditions does trial NCT05081167 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05081167?
The interventions under investigation include: Placebo (DRUG), REL-1017 (DRUG).
Who is sponsoring clinical trial NCT05081167?
This trial is sponsored by Relmada Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05081167 being conducted?
This trial has 10 study locations across Florida, Illinois, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05081167's enrollment target sits among peer trials
232 65th of 282 higher than 218 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI